IMNM Immunome, Inc.
IMNM Immunome, Inc.
Healthcare · Biotechnology
Desk view
Market read
POC $21.39 · VWAP $21.57 · -23.7% vs 12m avg buyer
Insiders quiet 0 buy / 0 sell · Form 4, 90d
Cluster Director, Officer sold $5.4M, Aug 6–12
Coverage
1 watchlist
IMNM Price Structure
Loading timeframes…
Peers
Every watchlist IMNM belongs to, members best 30-day change first — IMNM highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@monster-discoveries
Against street estimates
How IMNM's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
Recent news
Headlines about IMNM from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled today · Oct 17
- https://money.tmx.com/quote/IMNM:US/news/6468900456254811
- IMNM News Today | Why did Immunome stock go up today?
- Investor Relations - Immunome Inc.
- William Blair Initiates Coverage on Immunome With Outperform Rating | MarketScreener India
- Immunome, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | MarketScreener
“On or before” marks an article that arrived without a publish date — the date shown is when the desk pulled it, so the article is at least that old.
IMNM research tape
26 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.